News

Voyager DSLT is already available in select markets in the EU and the UK, and reduces the specialised training required with manual selective laser trabeculoplasty

Sexual harassment in the specialty remains high 5 years after a previous study, with higher frequencies of recent experiences and continued low reporting rates.

At the Envision Summit 2025 in San Juan, Puerto Rico, Oleg Alekseev, MD, PhD, talked about difficulties in diagnosing inherited retinal degenerations due to mutations in over 300 different genes.

The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March.

Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery

At the Envision Summit 2025 in San Juan, Puerto Rico, Ollya Fromal, MD, gave advice on how retina specialists can manage add-ons in their busy retina clinics.

The topline results from the COAST trial is anticipated in early Q2 of 2025.

According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria

Ying Han, MD, PhD discusses glaucoma management strategies, including transitioning care between ophthalmologists and optometrists, improving diagnosis, and the hope for future glaucoma developments.

Patients who underwent bilateral treatment experienced a higher rate of clinically relevant recovery, the authors reported.

PST-611, a first in class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator.

SightScore is a saliva test that looks at millions of genetic variants in the patient’s genome to create a personalized polygenic risk score for glaucoma.

At the Envision Summit 2025 in San Juan, Puerto Rico, Sharon Fekrat, MD, FACS, FASRS talked about multi-modal retinal and choroidal imaging to diagnose and identify neurodegenerative diseases using machine learning.

The focus in recent years has shifted to reducing the long-term burden of medical therapy, minimizing the risk of medication toxicity and persistent ocular surface disease.

Children experienced sudden vision loss, visual field constriction, nyctalopia and dyschromatopsia following febrile illness

Shah discusses several studies from the IRIS registry and plans for a retina program at next year's event to address the growing interest in retina procedures and techniques.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

At the Envision Summit 2025 in San Juan, Puerto Rico, Rachel Simpson, MD, talked about new developments in glaucoma treatment and really how to tailor glaucoma treatment to the patient.

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

At the Envision Summit 2025 in San Juan, Puerto Rico, Angela Zhu, MD, offered advice on cataract surgery for all ages, focusing on pediatrics.

OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.

Advancements in drug durability and patient care are closing treatment gaps.

Professor Anat Loewenstein, MD, speaks about her presentation from the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting

The partnership with the NHS eye patient servicer will help preregistration optometrists access training in community and hospital settings

AVT06 is Alvotech’s proposed biosimilar to Eylea (aflibercept) 2mg.